In a compelling presentation at LSI USA ’25, Dr. Denis Dufrane of Novadip Biosciences unveils groundbreaking progress in the field of regenerative medicine, specifically targeting complex bone defects.
Novadip has developed a pioneering osteobiologic platform capable of addressing both small and large skeletal injuries across adult and pediatric populations.
This platform not only promotes bone formation but also restores the full physiological process of healing—regulating bone resorption, angiogenesis, and immune response.
Central to their innovation are two therapeutic products. The first is an autologous cell-based solution, designed for severe bone damage where conventional treatments often lead to amputation.
This tissue-engineered therapy boasts a five-day shelf life at room temperature and aims to completely regenerate critical bone structures, with clinical cases demonstrating full limb restoration and return to normal life.
The second product is an allogenic, cell-derived bioactive powder, intended for more routine trauma and spinal fusion treatments.
Although it contains no viable cells, it leverages cell-secreted biomolecules to trigger the body’s own healing processes, establishing a novel pharmacological approach to bone therapy.
Currently in Phase 3 clinical trials, Novadip is poised for commercial launch by 2027.
Backed by over €60 million in funding, and having demonstrated success rates exceeding 88%, the company is setting its sights on disrupting billion-dollar markets in trauma and orthopedic care.
From its base in Belgium, Novadip is redefining the global landscape of bone regeneration.
Watch full video below:
